Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic paradigm shift over the past decade. Advances in our understanding of the underlying biology of NSCLC have revealed distinct molecular subtypes. A substantial proportion of NSCLC depends on oncogenic molecular aberratio...

Descripción completa

Detalles Bibliográficos
Autor principal: Rothschild, Sacha I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491691/
https://www.ncbi.nlm.nih.gov/pubmed/26018876
http://dx.doi.org/10.3390/cancers7020816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491691/
https://www.ncbi.nlm.nih.gov/pubmed/26018876
http://dx.doi.org/10.3390/cancers7020816

Ejemplares similares